Roche (OTCMKTS:RHHBY) Sets New 52-Week High Following Analyst Upgrade

Roche Holding AG (OTCMKTS:RHHBY) hit a new 52-week high during trading on Wednesday after Zacks Research upgraded the stock from a strong sell rating to a hold rating. The stock traded as high as $53.01 and last traded at $52.91, with a volume of 1279184 shares traded. The stock had previously closed at $51.61.

RHHBY has been the subject of a number of other research reports. HSBC reissued a “buy” rating and issued a $57.00 target price on shares of Roche in a research report on Wednesday, December 10th. Morgan Stanley reissued an “underweight” rating on shares of Roche in a report on Tuesday, December 2nd. Deutsche Bank Aktiengesellschaft raised shares of Roche from a “sell” rating to a “hold” rating in a research note on Tuesday, November 11th. JPMorgan Chase & Co. raised Roche from an “underweight” rating to a “neutral” rating in a research note on Monday, December 8th. Finally, Jefferies Financial Group cut Roche from a “hold” rating to a “moderate sell” rating in a report on Monday, October 27th. Three investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $57.00.

Institutional Investors Weigh In On Roche

Several institutional investors have recently modified their holdings of the stock. Curio Wealth LLC bought a new position in shares of Roche during the 3rd quarter valued at approximately $25,000. Oakworth Capital Inc. purchased a new position in Roche during the third quarter worth $57,000. First Horizon Advisors Inc. boosted its stake in Roche by 81.2% during the second quarter. First Horizon Advisors Inc. now owns 1,843 shares of the company’s stock worth $75,000 after buying an additional 826 shares during the period. Salomon & Ludwin LLC increased its position in Roche by 256.6% during the third quarter. Salomon & Ludwin LLC now owns 2,853 shares of the company’s stock valued at $129,000 after acquiring an additional 2,053 shares during the last quarter. Finally, Douglass Winthrop Advisors LLC purchased a new stake in shares of Roche in the third quarter valued at $201,000.

Roche Price Performance

The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.80. The company’s fifty day moving average price is $48.42 and its 200-day moving average price is $43.78.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.